- Home
- / Cidara Therapeutics
Cidara Therapeutics
Stock Price
$13.4
2024-10-29
Market Capitalization
$94.2 M
2024-10-29
Revenue
$1.3 M
FY, 2024
Cidara Therapeutics Summary
Company Summary
- Overview
- Cidara Therapeutics is developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Its initial focus is on devastating fungal infections that often complicate cancer and transplant treatments.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- San Diego, CA, US | view all locations
- Website
- http://cidara.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jeffrey Stein, President and Chief Executive Officer, Director
Nicole Davarpanah, Senior Vice President, Translational Research & Development
Taylor Sandison, Chief Medical Officer
LocationsView all
1 location detected
San Diego, CA HQ
United States
6310 Nancy Ridge Dr
Cidara Therapeutics Financials
Summary Financials
- Net income (Q3, 2025)
- ($83.2M)
- Cash (Q3, 2025)
- $293.7M
- EBIT (Q3, 2025)
- ($88.6M)
- Enterprise value
- ($197.4M)